Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Roxadustat Shows Activity Against Chemotherapy-Induced Anemia in Non-Myeloid Malignancies

August 26th 2021

The first-in-class small molecule HIF-PHI inhibitor roxadustat demonstrated promising efficacy with favorable tolerability when used in the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies, meeting the primary end point of the phase 2 WHITNEY trial.

FDA Grants Priority Review to Asciminib for Chronic Myeloid Leukemia

August 25th 2021

The FDA has granted priority review to a new drug application seeking the approval of asciminib for the treatment of patients with chronic myeloid leukemia.

Mosunetuzumab Elicits High, Durable Responses in Multiply Relapsed Follicular Lymphoma

August 24th 2021

Fixed-duration treatment with mosunetuzumab elicited encouraging responses with acceptable safety when used in patients with multiply relapsed follicular lymphoma.

Chemotherapy-Free Strategies Chart a New Course for Ph-Positive ALL

August 24th 2021

A new era for patients with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia may be on the horizon as investigative efforts aimed away from chemotherapy-based regimens prove efficacious.

Sequencing Therapies in Relapsed/Refractory ALL

August 24th 2021

Ibrahim Aldoss, MD, and James K. McCloskey, MD, share thoughts on how to effectively sequence available treatment modalities for acute lymphocytic leukemia in various patient populations.

Salvage Therapies in R/R ALL, Including CAR T-Cell Therapy

August 24th 2021

Drs Aldoss and McKloskey describe treatments that can be used in the salvage setting of acute lymphocytic leukemia, including CAR T-cell therapy.

Frontline Therapy for CLL: Emerging Agents and Approaches

August 23rd 2021

Key opinion leaders look forward to upcoming improvements in the frontline management of chronic lymphocytic leukemia.

Which Path to Take in Frontline Therapy for CLL?

August 23rd 2021

Experts reflect on core decisions inherent in selecting frontline therapy for patients with CLL, specifically regarding the use of BTK inhibitors, BCL2 inhibitors, anti-CD20 agents, and chemoimmunotherapy.

FDA Grants Priority Review to Abatacept for Prevention of Acute GVHD

August 23rd 2021

The FDA has granted a priority review designation to a supplemental biologics license application seeking the approval of abatacept for the prevention of moderate to severe acute graft-versus-host disease in patients aged 6 years and older who are receiving unrelated donor hematopoietic stem cell transplantation.

Exploring Emerging Data in DLBCL

August 23rd 2021

A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.

Looking at the Big Picture in DLBCL

August 23rd 2021

Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.

Treating Patients Post CAR T Therapy

August 23rd 2021

David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

Success Beyond Science: Becoming a Hematologist/Oncologist

August 22nd 2021

The ability to reflect and boldly choose a professional identity should be discussed, encouraged, and nurtured in every individual.

Clonal Hematopoiesis Confers Substantial Risks in Healthy Individuals and Patients with Cancer

August 20th 2021

Peter G. Miller, MD, PhD, discusses the characteristics and risks associated with clonal hematopoiesis and risk-stratification efforts for patients with cancer who are at risk of developing therapy-related secondary malignancies from clonal hematopoiesis.

Mosunetuzumab Elicits Durable Response in Elderly Patients With DLBCL

August 20th 2021

Updated outcomes from the ongoing phase 1/2 GO40554 trial show that mosunetuzumab monotherapy demonstrated promising efficacy and a tolerable safety for elderly/unfit patients with previously untreated first-line diffuse large B-cell lymphoma.

Treatment in Older Patients with High-Risk MDS

August 20th 2021

Azra Raza, MD, discusses considerations for use of hypomethylating agents in older patients with high-risk myelodysplastic syndrome.

Role of Transplant in MDS

August 20th 2021

The panel of experts comment on the role of transplant in patients with myelodysplastic syndrome.

High-Risk MDS: Clinical Efficacy Data

August 19th 2021

Mikkael A. Sekeres, MD, discusses his approach to treatment in patients with high-risk MDS incorporating efficacious clinical trial data.

Clinical Implications of High-Risk MDS

August 19th 2021

Experts in the treatment of MDS discuss the clinical implications and treatment selection for patients with high-risk MDS.

The Role of Venetoclax for Treatment of AML

August 19th 2021

Renowned experts in hematology-oncology provide insight into the practical implications of treating acute myeloid leukemia with the current standard-of-care regimen using venetoclax.